Vasileios Askoxylakis: Promising clinical data from the Phase 1 study of the CCR7 targeting antibody-drug conjugate JBH492

Vasileios Askoxylakis, Vice President, Global Head Oncology Early Clinical Development at Servier, shared on LinkedIn:

“Very excited to see clinical data from the Phase 1 study of the CCR7 targeting antibody-drug conjugate JBH492 presented for the first time at AACR24. I had the honor and privilege to work with an amazing team and lead the IND and the first-in-human clinical trial of JBH492 during my tenure as Clinical Program Leader at Novartis Institutes for Biomedical Research. Congratulations to my colleagues and friends at Novartis!”

Source: Vasileios Askoxylakis/LinkedIn